(CASE REPORT): A CASE REPORT ON DRAMATIC RESPONSE OF REFRACTORY PANUVEITIS OF BEHCET DISEASE TO SHORT-TERM THERAPY WITH INFLIXIMAB FOLLOWED BY CELLCEPT

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

MOGHIMI J.; DARAEI GH.R.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Koomesh Year:2009 | Volume:10 | Issue:3 (31) Page(s): 225-227

Download Full-Text

Persian Verion

View:

737

Download:

Cites:

Information Journal Paper

Title

(CASE REPORT): A CASE REPORT ON DRAMATIC RESPONSE OF REFRACTORY PANUVEITIS OF BEHCET DISEASE TO SHORT-TERM THERAPY WITH INFLIXIMAB FOLLOWED BY CELLCEPT

Author(s)

MOGHIMI J. | DARAEI GH.R. | Issue Writer Certificate

Keywords

PANUVEITISQ3

BEHCET DISEASEQ3

CELLCEPTQ3

INFLIXIMABQ3

Abstract

Behcet disease (BD) is a multisystem vasculitic syndrome with clinical triad of oral aphthus ulcer, genital ulcer, and eye involvement. Uveitis of BD may be particularly resistant to corticosteroids and immunosuppressants with a rapid progression to loss of vision in 10-25% of the cases. In recent years, INFLIXIMAB is a very useful drug for refractory eye involvement of BD and some studies recommend CELLCEPT for this reason.Here, we reported a 40 years old man with known BD, referred to our Clinic with severe bilateral PANUVEITIS. His eye involvement was refractory to conventional therapy in 15 months follow-up; then he was switched to INFLIXIMAB, in an attempt to control his disease. INFLIXIMAB (3mg/kg) was given at 0, 4, 8 weeks (three doses) together with Azathioprin. Very soon after the first infusion, we have found a remarkable ophthalmologic response. We have prescribed CELLCEPT after the third infusion and discontinued Azathioprin and INFLIXIMAB.14 months after the last infusion, no significant changes were found in ophthalmologic examination. Our observation highlights a difference in the effect of CELLCEPT in PANUVEITIS of BD.

Cites

No record.

References

No record.

Cite

APA: Copy

MOGHIMI, J., & DARAEI, GH.R.. (2009). (CASE REPORT): A CASE REPORT ON DRAMATIC RESPONSE OF REFRACTORY PANUVEITIS OF BEHCET DISEASE TO SHORT-TERM THERAPY WITH INFLIXIMAB FOLLOWED BY CELLCEPT. KOOMESH, 10(3 (31)), 225-227. SID. https://sid.ir/paper/37267/en

Vancouver: Copy

MOGHIMI J., DARAEI GH.R.. (CASE REPORT): A CASE REPORT ON DRAMATIC RESPONSE OF REFRACTORY PANUVEITIS OF BEHCET DISEASE TO SHORT-TERM THERAPY WITH INFLIXIMAB FOLLOWED BY CELLCEPT. KOOMESH[Internet]. 2009;10(3 (31)):225-227. Available from: https://sid.ir/paper/37267/en

IEEE: Copy

J. MOGHIMI, and GH.R. DARAEI, “(CASE REPORT): A CASE REPORT ON DRAMATIC RESPONSE OF REFRACTORY PANUVEITIS OF BEHCET DISEASE TO SHORT-TERM THERAPY WITH INFLIXIMAB FOLLOWED BY CELLCEPT,” KOOMESH, vol. 10, no. 3 (31), pp. 225–227, 2009, [Online]. Available: https://sid.ir/paper/37267/en

Related Journal Papers